Figure 2From: Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout Mean anti-pegloticase Ab titers over time among serum uric acid (sUA) responders and nonresponders (and placebo-treated patients) receiving biweekly (top panel) and monthly (bottom panel) pegloticase. Back to article page